The new era of personalized medicine: 10 years later

Personalized Medicine

Volumn 6, Issue 4, 2009, Pages 423-428

  Jørgensen, Jan Trøst ^a   Winther, Henrik ^b  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b AGILENT TECHNOLOGIES   (United States)

Author keywords

Companion diagnostics; Efficacy; Molecular diagnostics; Oncology; Personalized medicine; Pharmacodiagnostics; Pharmacotherapy; Safety; Stratified medicine

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; ATORVASTATIN; AZATHIOPRINE; CARBAMAZEPINE; CETUXIMAB; DASATINIB; ESTROGEN RECEPTOR; IRINOTECAN; MARAVIROC; RASBURICASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN CITRATE; TRASTUZUMAB; VALPROIC ACID; WARFARIN;

ADVANCED CANCER; ARTICLE; ASTHMA; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL MEDICINE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EUROPEAN UNION; HEALTH CARE COST; HEALTH EDUCATION; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MEDICAL LITERATURE; MENTAL DISEASE; MORTALITY; NEOPLASM; PERSONALIZED MEDICINE; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; REIMBURSEMENT; STOMACH CANCER;

EID: 67949100552     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.09.24     Document Type: Article

References (15)

1. Langreth R, Waldholz M: New era of personalized medicine - targeting drugs for each unique genetic profile. Oncologist 4, 426-427 (1999).
2. Hu SX, Foster T, Kieffaber A: Pharmacogenomics and personalized medicine: mapping of future value creation. BioTechniques 39, 1-6 (2005).
3. Trusheim MR, Berndt ER, Douglas FL: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 6, 287-293 (2007).
4. Jørgensen JT: Are we approaching the post-blockbuster era? - pharmacodiagnostics and rational drug development. Expert Rev. Mol. Diagn. 8, 689-695 (2008).
5. Jensen EV, Desombre ER, Hurst DJ et al.: Estrogen-receptor interaction in target tissue. Arch. Anat. Microsc. Morphol. Exp. 56, 547-569 (1967).
6. Lerner HJ, Band PR, Israel L, Leung BS: Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer. Cancer Treat. Rep. 60, 1431-1435 (1976).
7. Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
8. Dahabreh IJ, Linardou H, Siannis F et al.: Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 13, 620-630 (2008).
9. Van Cutsem E, Kang H, Chung H et al.: Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. J. Clin. Oncol. 27(18S) (2009) (Abstract LBA4509).
10. Flockhart DA, Skaar T, Berlin DS et al.: Clinically available pharmacogenomics tests. Clin. Pharmacol. Ther. (2009).
11. Spear BB, Heath-Chiozzi M, Huff J: Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201-204 (2001).
12. Sikora K: Personalized cancer therapy - key to the future. Pharmacogenomics 5, 225-228 (2004).
13. Jørgensen JT: From blockbuster medicine to personalized medicine. Per. Med. 5, 55-63 (2008).
14. Jørgensen JT, Nielsen KV, Ejlertsen B: Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anti-cancer therapy in breast cancer. Oncologist 12, 397-405 (2007).
15. Davis JC, Furstenthal L, Desai AA et al.: The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat. Rev. Drug Discov. 8, 279-286 (2009).